Ameriprise
CRMD icon

Ameriprise’s CorMedix CRMD Stock Holding History

Ameriprise’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.17M Sell
276,287
-1,497
-0.5% -$11.8K ﹤0.01% 3033
2026
Q1 		$1.89M Sell
277,784
-1,242
-0.4% -$9.18K ﹤0.01% 2987
2025
Q4 		$3.25M Buy
279,026
+42,616
+18% +$471K ﹤0.01% 2742
2025
Q3 		$2.75M Buy
236,410
+58,688
+33% +$710K ﹤0.01% 2825
2025
Q2 		$2.19M Buy
177,722
+62,322
+54% +$688K ﹤0.01% 2904
2025
Q1 		$711K Buy
115,400
+102,644
+805% +$1.06M ﹤0.01% 3358
2024
Q4 		$103K Buy
+12,756
New +$127K ﹤0.01% 3950
2024
Q3 		– Sell
-11,697
Closed -$50.6K – 3946
2024
Q2 		$50.6K Buy
+11,697
New +$59.4K ﹤0.01% 3814
2023
Q4 		– Sell
-10,700
Closed -$39.6K – 3909
2023
Q3 		$39.6K Buy
+10,700
New +$42.6K ﹤0.01% 3845
2023
Q1 		– Sell
-17,800
Closed -$75K – 3957
2022
Q4 		$75K Sell
17,800
-9,700
-35% -$34.3K ﹤0.01% 3835
2022
Q3 		$78K Sell
27,500
-633
-2% -$2.63K ﹤0.01% 3861
2022
Q2 		$113K Sell
28,133
-6,500
-19% -$24.1K ﹤0.01% 3763
2022
Q1 		$190K Hold
34,633
– – ﹤0.01% 3765
2021
Q4 		$158K Sell
34,633
-15,187
-30% -$75.4K ﹤0.01% 3825
2021
Q3 		$231K Sell
49,820
-7,570
-13% -$44.1K ﹤0.01% 3669
2021
Q2 		$394K Buy
57,390
+3,195
+6% +$25.4K ﹤0.01% 3546
2021
Q1 		$542K Buy
54,195
+32,805
+153% +$345K ﹤0.01% 3368
2020
Q4 		$151K Buy
+21,390
New +$145K ﹤0.01% 3656

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Ameriprise's CRMD Position: Q2 2026 in Review

Ameriprise reduced its CorMedix (CRMD) stake by 0.54% in Q2 2026, selling an estimated $11.8K and leaving 276,287 shares worth $2.17M. The position accounts for ﹤0.01% of the portfolio, ranked #3033.

Ameriprise first reported a position in CRMD in Q4 2020 and has held it in 18 quarters since. The position peaked at $3.25M in Q4 2025. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

  • Ameriprise held 276,287 shares of CorMedix worth $2.17M as of Q2 2026.
  • Ameriprise sold 1,497 CorMedix shares in Q2 2026, an estimated $11.8K.
  • CorMedix made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3033 holding.
  • Ameriprise first reported a position in CorMedix in Q4 2020 and has held it in 18 quarters since.
  • Ameriprise's CorMedix position peaked at $3.25M in Q4 2025.
  • 194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.